

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

5TGM1

RRID:CVCL_VI66

Type: Cell Line

Proper Citation

RRID:CVCL_VI66

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_VI66

Proper Citation: RRID:CVCL_VI66

Description: Cell line 5TGM1 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Disease: Mouse multiple myeloma

Defining Citation: [PMID:9177864](#)

Comments: Characteristics: Produces IgG2b kappa.

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: 5TGM1

Synonyms: 5T33 cell line

Cross References: BTO:BTO_0006375, ChEMBL-Cells:ChEMBL4482254, PubChem_Cell_line:CVCL_VI66, Wikidata:Q93308507

ID: CVCL_VI66

Record Creation Time: 20220427T215057+0000

Record Last Update: 20260904T021116+0000

Ratings and Alerts

No rating or validation information has been found for 5TGM1.

No alerts have been found for 5TGM1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sabol HM, et al. (2026) Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. *Journal of experimental & clinical cancer research* : CR, 45(1), 31.

Wang J, et al. (2026) Clostridium butyricum alleviates multiple myeloma by remodeling the bone marrow microenvironment and inhibiting PI3K/AKT pathway through the gut?bone axis. *Gut microbes*, 18(1), 2609455.

Shah UA, et al. (2026) A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model. *Cancer discovery*, 16(4), 697.

Gu H, et al. (2026) FAP?+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(18), e06239.

Fairfield H, et al. (2026) Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans. *Cancer prevention research (Philadelphia, Pa.)*, 19(6), 339.

Anloague A, et al. (2025) A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma. *Haematologica*, 110(4), 952.

Wang L, et al. (2025) Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8+ T-Cell-Mediated Immunity against Multiple Myeloma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(42), e10888.

Oudaert I, et al. (2025) PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism. *Molecular oncology*.

Lin C, et al. (2023) S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes. *Cancer research communications*, 3(3), 420.

Sabol HM, et al. (2022) Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. *Neoplasia* (New York, N.Y.), 28, 100785.

Lo CH, et al. (2021) Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival. *Cancer research*, 81(9),

2415.

Sabol HM, et al. (2021) Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. *Cancer research*, 81(19), 5102.